In the previous articles of our Beyond FDA series, we explored seven realities that many Healthcare AI companies discover too late: FDA clearance does not guarantee market adoption. Great products fail without a reimbursement strategy. AI accuracy alone is no longer enough. Clinical validation is what earns trust. Trust itself comes from Key Opinion Leaders, not marketing. Clearance, validation, and adoption are three separate pillars that must be earned independently. The best algorithm still loses to the best-integrated one. And CIOs buy risk reduction before they buy innovation. This brings us to the final article in our Enterprise Healthcare phase, and the pattern that ties the last three articles together: Technical success and workflow success are not the same thing.
(Beyond FDA Series, Part 8)
The Algorithm Isn't Waiting on the Algorithm
By the time most Healthcare AI companies reach a real hospital deployment, the model itself is the easy part. It's already been trained, validated, and cleared. What actually determines the go-live date is something almost nobody budgets time for:
Does this thing have a place to actually run?
Where Great AI Goes to Wait
A finished, cleared, validated algorithm still has to get through:
✔ PACS approval: will the imaging vendor allow a third-party AI result to display inside their viewer?
✔ EHR data governance: will the hospital's data team approve a new structured data flow into the patient record?
✔ Vendor firewalls: will the existing imaging or IT vendor's contract terms even permit a competing or adjacent tool to connect?
None of these are AI problems. They're organizational and contractual problems that sit squarely between a working model and a used one.
Why This Bottleneck Is Invisible Until It Isn't
Founders test their AI against clean, de-identified datasets in a research environment where none of these constraints exist. The model performs. The paper gets published. The FDA clears it.
Then it meets a real hospital's PACS vendor, whose contract requires a separate integration agreement and a six-figure fee just to enable a third-party AI overlay, a fee and timeline nobody accounted for in the go-to-market plan.
This is the moment "we're ready to deploy" turns into a nine-month vendor negotiation that has nothing to do with clinical performance.
What Founders Consistently Underestimate
- PACS and EHR vendors often have their own commercial incentives around who gets to integrate, and on what terms
- Hospital data governance committees move on their own timeline, independent of clinical urgency
- "Technically compatible" and "contractually permitted" are two different approvals, and both are required
Companies that map these dependencies before a pilot begins move faster than companies that discover them mid-deployment.
Final Thought
A validated, FDA-cleared, clinically trusted AI tool can still sit unused for months: not because it doesn't work, but because it doesn't yet have a sanctioned place to work.
Great AI still needs a place to work.
Interoperability isn't a technical checkbox to clear once. It's an ongoing negotiation with every PACS vendor, EHR system, and IT governance committee standing between a finished product and a functioning deployment, and it deserves the same planning discipline as the clinical and regulatory work that came before it.
Next in the Beyond FDA Series:
Why ACR Alignment Is Becoming A Competitive Advantage For AI Vendors
#HealthcareAI #Interoperability #HealthIT #PACS #EHR #DigitalHealth #HealthcareInnovation #ArtificialIntelligence #MedTech #SaMD #RadiologyAI #QscriptionTechnologies